JP6272820B2 - Ｈｉｖ特異的ｔ細胞応答のモニタリング方法 - Google Patents

Ｈｉｖ特異的ｔ細胞応答のモニタリング方法 Download PDF

Info

Publication number
JP6272820B2
JP6272820B2 JP2015502244A JP2015502244A JP6272820B2 JP 6272820 B2 JP6272820 B2 JP 6272820B2 JP 2015502244 A JP2015502244 A JP 2015502244A JP 2015502244 A JP2015502244 A JP 2015502244A JP 6272820 B2 JP6272820 B2 JP 6272820B2
Authority
JP
Japan
Prior art keywords
response
hiv
cells
peptide
cytokines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015502244A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513100A (ja
Inventor
リオル、マルタ ルイス
リオル、マルタ ルイス
ブランデル、クリスティアン
イバロンド、ハビエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IrsiCaixa Institut de Recerca de la Sida
Original Assignee
IrsiCaixa Institut de Recerca de la Sida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IrsiCaixa Institut de Recerca de la Sida filed Critical IrsiCaixa Institut de Recerca de la Sida
Publication of JP2015513100A publication Critical patent/JP2015513100A/ja
Application granted granted Critical
Publication of JP6272820B2 publication Critical patent/JP6272820B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015502244A 2012-03-23 2013-03-22 Ｈｉｖ特異的ｔ細胞応答のモニタリング方法 Active JP6272820B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261615038P 2012-03-23 2012-03-23
EP12382109 2012-03-23
US61/615,038 2012-03-23
EP12382109.2 2012-03-23
PCT/EP2013/056110 WO2013139972A1 (en) 2012-03-23 2013-03-22 Method for monitoring hiv specific t cell responses

Publications (2)

Publication Number Publication Date
JP2015513100A JP2015513100A (ja) 2015-04-30
JP6272820B2 true JP6272820B2 (ja) 2018-01-31

Family

ID=49221879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502244A Active JP6272820B2 (ja) 2012-03-23 2013-03-22 Ｈｉｖ特異的ｔ細胞応答のモニタリング方法

Country Status (9)

Country Link
US (1) US9709577B2 (enExample)
EP (1) EP2828656B1 (enExample)
JP (1) JP6272820B2 (enExample)
CN (1) CN104272108A (enExample)
CA (1) CA2868066C (enExample)
HK (1) HK1205264A1 (enExample)
IN (1) IN2014DN08394A (enExample)
MX (1) MX2014011484A (enExample)
WO (1) WO2013139972A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101777256B1 (ko) 2016-07-07 2017-09-12 대한민국(농림축산식품부 농림축산검역본부장) T 세포의 병원체 감염 세포 독성능 평가 방법
KR101777252B1 (ko) 2016-07-07 2017-09-12 대한민국(농림축산식품부 농림축산검역본부장) T 세포의 prrsv 증식 억제능 평가 방법
CN110308285B (zh) * 2019-07-12 2022-07-26 中国人民解放军军事科学院军事医学研究院 用于预测重度电离辐射损伤死亡的标志物组合
AU2023232911A1 (en) * 2022-03-09 2024-10-17 Fundació Privada Institut De Recerca Sobre Immunopatologies-Caixa Irsicaixa Boosted immune monitoring methods for assaying antigen-specific t cell responses
CN115754303A (zh) * 2022-11-24 2023-03-07 复旦大学附属华山医院 基于Th1和Th2细胞因子组合的评价方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624456D0 (en) * 1996-11-25 1997-01-15 Isis Innovation Assay method
CN1230444C (zh) * 1998-11-16 2005-12-07 德克萨斯州立大学董事会 含有hiv细胞毒t淋巴细胞表位的hiv多肽或肽或其多聚核苷酸表达构建体的用途
AU2002952548A0 (en) * 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
WO2005017192A2 (en) * 2003-08-14 2005-02-24 The General Hospital Corporation Screening for gestational disorders
EP1767937A1 (en) * 2005-09-27 2007-03-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of diagnosis of tuberculosis related immune restoration syndrome (IRS)
AU2007229263B2 (en) * 2006-03-20 2012-08-09 St Vincent's Hospital Sydney Limited A method for detecting antigen-specific or mitogen-activated T cells
WO2008127840A2 (en) * 2007-03-22 2008-10-23 University Of Iowa Research Foundation Flavivirus ns5a proteins for the treatment of hiv
US20090263828A1 (en) * 2008-04-16 2009-10-22 Franco Lori Novel assay for precursor T-cells having high proliferative capacity (PHPC-asay)
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
CN104623666A (zh) * 2011-04-29 2015-05-20 西莱克塔生物科技公司 用于诱导调节性b细胞的致耐受性合成纳米载体

Also Published As

Publication number Publication date
MX2014011484A (es) 2015-09-23
CA2868066C (en) 2019-11-12
CN104272108A (zh) 2015-01-07
JP2015513100A (ja) 2015-04-30
CA2868066A1 (en) 2013-09-26
US9709577B2 (en) 2017-07-18
IN2014DN08394A (enExample) 2015-05-08
HK1205264A1 (en) 2015-12-11
EP2828656A1 (en) 2015-01-28
US20150057175A1 (en) 2015-02-26
EP2828656B1 (en) 2019-09-18
WO2013139972A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
Arunachalam et al. T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers
Fan et al. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection
Huygens et al. Functional exhaustion limits CD4+ and CD8+ T-cell responses to congenital cytomegalovirus infection
US8030005B2 (en) Method for detecting antigen specific or mitogen-activated T cells
US8975069B2 (en) Method for identifying antigen-specific regulatory T cells
JP6272820B2 (ja) Ｈｉｖ特異的ｔ細胞応答のモニタリング方法
Materne et al. Cytomegalovirus-specific T cell epitope recognition in congenital cytomegalovirus mother-infant pairs
Fourati et al. Development of an IFN-γ ELISpot assay to assess varicella-zoster virus-specific cell-mediated immunity following umbilical cord blood transplantation
Burton et al. Rapid qualitative and quantitative analysis of T-cell responses in HIV-1-infected individuals receiving successful HAART and HIV-1 sero-negative controls: Concomitant assessment of perforin, IFN-γ and IL-4 secretion
ES2753249T3 (es) Método para seguir las respuestas de células T específicas al VIH
Sandberg et al. Longitudinal characterization of humoral and cellular immunity in hospitalized COVID-19 patients reveal immune persistence up to 9 months after infection
Brown et al. Understanding measles virus: from isolation to immunological cellular mechanisms and immunisation 1954–2024
Bartovska et al. Antiretroviral Treatment of HIV Infection Does Not Influence HIVSpecific Immunity but Has an Impact on Non-Specific Immune Activation
Richard Toll-like receptor (TLR) 7 and TLR8 stimulation of mucosal-associated invariant T cells and gamma delta T cells: a role in HIV susceptibility
CN119384602A (zh) 用于测定抗原特异性t细胞应答的加强免疫监测方法
Jimenez-Leon et al. TLR Agonists Enhance HIV-Specific T-Cell Response Mediated by Plasmacytoid Dendritic Cells in Diverse HIV-1 Disease Progression Phenotypes
Ruiz-Mateos et al. Toll-like Receptor Agonists Enhance HIV-specific T Cell Response Mediated by Plasmacytoid Dendritic Cells in Diverse HIV-1 Disease Progression Phenotypes
Zadrazil Human Cytomegalovirus as a driving force towards Immunosenescence
Patterson et al. Distinctive in vitro effects of T-cell growth cytokines on cytomegalovirus-stimulated T-cell responses of HIV-infected HAART recipients
Girard et al. Altered frequency of CD24highCD38high transitional B cells in patients with cardiac involvement of chronic Chagas disease
Xu et al. CD38+ HLA-DR+ CD8+ T Cells induced by IL-15 exert liver injury through NKG2D in chronic hepatitis B cirrhosis
Murphy Human myeloid cell and innate lymphocyte responses to mycobacterial vaccination or infection
Darboe Natural Killer cell function after vaccination in an African (Gambian) population.
Jayasooriya Immune control of epstein-barr virus infection in African children
Warszawski et al. Gag-specific CD8 T-cell proliferation is associated with higher peripheral blood levels of TGF-β and gut-homing T cells in youths perinatally infected with HIV-1–The ANRS-EP38-IMMIP Study

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160321

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180104

R150 Certificate of patent or registration of utility model

Ref document number: 6272820

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250